Drugs / HLX37
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07274813 | Dec 2025 → Mar 2027 expected | non-small cell lung carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-07-10 | Shanghai Henlius Biotech | Regulatory Henlius’ PD-L1×VEGF Bispecific Antibody HLX37 Receives NMPA IND Approval for a Phase 1 Study, Advancing Next-Generation IO Combination Strategy henlius.com ↗
has been approved by the China’s National Medical Products Administration (NMPA). |
| 2025-12-01 | Shanghai Henlius Biotech | Regulatory Henlius Receives the NMPA IND Approval for Its Innovative PD-L1/VEGF Bispecific Antibody HLX37 henlius.com ↗ |
| 2025-04-28 | Shanghai Henlius Biotech | Results Preclinical Results of Henlius’ Multiple Innovative Candidates Debut at AACR 2025 henlius.com ↗
It conferred robust tumor inhibition activity and dose-dependent tumor suppression in the MDA-MB231 and NCI-H292 models. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-10 | Shanghai Henlius Biotech | Henlius’ PD-L1×VEGF Bispecific Antibody HLX37 Receives NMPA IND Approval for a Phase 1 Study, Advancing Next-Generation IO Combination Strategy henlius.com ↗ |
| 2025-12-30 | Shanghai Henlius Biotech | Henlius Doses First Patient in Phase 1 Trial of Novel PD-1xVEGF Bispecific Antibody HLX37 for Solid Tumors henlius.com ↗ |
| 2025-12-01 | Shanghai Henlius Biotech | Henlius Receives the NMPA IND Approval for Its Innovative PD-L1/VEGF Bispecific Antibody HLX37 henlius.com ↗ |
| 2025-04-28 | Shanghai Henlius Biotech | Preclinical Results of Henlius’ Multiple Innovative Candidates Debut at AACR 2025 henlius.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX37 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07274813 ↗ |
| Modality | Monoclonal antibody | “HLX37 (Recombinant Human Bispecific Antibodies Against PD-L1 and VEGF)” NCT07274813 ↗ |
| Route | Intravenous | “HLX37 will be administered as an intravenous (IV) infusion.” NCT07274813 ↗ |